14th March
TriviumVet’s felycin®-CA1 has been granted conditional approval by the U.S. Food and Drug Administration (FDA). This marks a significant milestone in feline cardiac care as the...
TriviumVet:
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations
28th July
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations You can read the full article below....
Congratulations to NC State’s Olby as she Wins 2023 AVMA Career Achievement in Canine Research Award
18th July
Dr. Olby, is a professor of veterinary neurology and neurosurgery at the North Carolina Veterinary School, she has authored or co-authored more than 200 scientific papers, most...
Cutting edge Feline Hypertrophic Cardiomyopathy Research to be presented to the American College of Veterinary Internal Medicine (ACVIM)
20th April
Two exciting pieces of feline hypertrophic cardiomyopathy (HCM) research are to be presented to the American College of Veterinary Internal Medicine (ACVIM) this year on their...
TriviumVet CEO Louise Grubb wins IMAGE PwC Business Woman of the Year 2023 Award
17th April
Serial entrepreneur Louise Grubb, founder and CEO of the game-changing companion animal diagnosis and treatment business TriviumVet, was awarded the overall title of Businesswoman...
TriviumVet appoint healthcare powerhouse Helen Ryan as Chairperson of their board
17th February
TriviumVet™ are delighted to announce that Helen Ryan has been appointed as our new board Chairperson. CEO Louise Grubb comments of the appointment “Having a Chairperson of...
Understanding Feline HCM: Prognosis, Genetic Mutations and Emerging Treatment Options Dr. Joshua Stern, UC Davis
3rd February
Dr. Joshua Sterns presentation from VMX 2023
Spotlight Series - The "REVERSE" Feline Chronic Kidney Disease Study at The Ohio State University Veterinary School
17th November
Spotlight on REVERSE The first post in our Spotlight Series where we shine a light on one of our Clinical Trials or Projects. One of our most exciting projects at TriviumVet is...
RAPACAT HCM trial results unveiled at International Cardio-Renal Veterinary Symposium (ICVS) 2022
1st October
Feline hypertrophic cardiomyopathy remains the greatest unmet need in veterinary cardiology, affecting around 15% of all pet cats. After two years of collaboration between...
TriviumVet to exhibit at VMX 2023. TriviumVet will be participating in the New Exhibitors Area – Zone A – Booth 5203
19th September
TriviumVet to exhibit at VMX 2023 in Orlando Florida Veterinary professionals worldwide are set to learn the latest in veterinary medicine at VMX 2023. The North American...
A great summary by FDA's Dr. Christopher Loss on Conditionally Approved Animal Drugs and what it means to use them
6th September
Abstract The purpose of this article is to provide veterinarians with an understanding of what it means to use a conditionally approved drug. This article summarizes information...
TriviumVet:
Congratulations to NC State’s Olby as she Wins 2023 AVMA Career Achievement in Canine Research Award
18th July
Dr. Olby, is a professor of veterinary neurology and neurosurgery at the North Carolina Veterinary School, she has authored or co-authored more than 200 scientific papers, most...
Cutting edge Feline Hypertrophic Cardiomyopathy Research to be presented to the American College of Veterinary Internal Medicine (ACVIM)
20th April
Two exciting pieces of feline hypertrophic cardiomyopathy (HCM) research are to be presented to the American College of Veterinary Internal Medicine (ACVIM) this year on their...
TriviumVet CEO Louise Grubb wins IMAGE PwC Business Woman of the Year 2023 Award
17th April
Serial entrepreneur Louise Grubb, founder and CEO of the game-changing companion animal diagnosis and treatment business TriviumVet, was awarded the overall title of Businesswoman...
TriviumVet appoint healthcare powerhouse Helen Ryan as Chairperson of their board
17th February
TriviumVet™ are delighted to announce that Helen Ryan has been appointed as our new board Chairperson. CEO Louise Grubb comments of the appointment “Having a Chairperson of...
Understanding Feline HCM: Prognosis, Genetic Mutations and Emerging Treatment Options Dr. Joshua Stern, UC Davis
3rd February
Dr. Joshua Sterns presentation from VMX 2023
Spotlight Series - The "REVERSE" Feline Chronic Kidney Disease Study at The Ohio State University Veterinary School
17th November
Spotlight on REVERSE The first post in our Spotlight Series where we shine a light on one of our Clinical Trials or Projects. One of our most exciting projects at TriviumVet is...
RAPACAT HCM trial results unveiled at International Cardio-Renal Veterinary Symposium (ICVS) 2022
1st October
Feline hypertrophic cardiomyopathy remains the greatest unmet need in veterinary cardiology, affecting around 15% of all pet cats. After two years of collaboration between...
TriviumVet to exhibit at VMX 2023. TriviumVet will be participating in the New Exhibitors Area – Zone A – Booth 5203
19th September
TriviumVet to exhibit at VMX 2023 in Orlando Florida Veterinary professionals worldwide are set to learn the latest in veterinary medicine at VMX 2023. The North American...
A great summary by FDA's Dr. Christopher Loss on Conditionally Approved Animal Drugs and what it means to use them
6th September
Abstract The purpose of this article is to provide veterinarians with an understanding of what it means to use a conditionally approved drug. This article summarizes information...